JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2020, 69(5):211-217 | DOI: 10.36290/csf.2020.029

Development and validation of a HPLC method for quantifica-tion of degradation impurities of salbutamol sulfate with following long-term stability studies in multicomponent cough syrup

Ivan Bezruk1,*, Anna Materiienko1, Svitlana Gubar1, Vera Bunyatyan2,3, Sergiy M. Kovalenko2,4, Victoriya Georgiyants1, Liudas Ivanauskas5
1 National University of Pharmacy, Department of Pharmaceutical Chemistry, Kharkiv, Ukraine
2 Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
3 Federal State Budgetary Institution "Scientific Centre for Expert Evaluation of Medicinal Products" of the Ministry of Health of the Russian Federation, Moscow, Russia
4 V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
5 Lithuanian University of Health Sciences, Kaunas, Lithuania

Medicines containing both a herbal extract and a synthetic substance are in high demand due to their beneficial effects and synergism. The novel combination of salbutamol sulfate and Hedera helix extracts seems to be prospective in terms of pharmacological activity. But for quality assurance, impurities of the synthetic component have to be determined and quantified. Plant extracts consist of various phytochemical components, therefore, it is more complicated to develop a selective analytical method due to the sample matrix. To prove the safety and efficacy of the dosage form, a new HPLC method for analysis of salbutamol sulfate impurities was developed and validated. The method was used to estimate the safety of the novel syrup by performing long-term stability studies for 24 months. Obtained results indicated the absence in both significant reducing of the main components content and increasing of related substances level. Also, force degradation was carried out to prognosticate the possibility of impurities producing.

Keywords: long-term stability study; salbutamol sulfate; impurities; multicomponent dosage form; cough syrup; HPLC

Received: July 29, 2020; Accepted: October 12, 2020; Published: May 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bezruk I, Materiienko A, Gubar S, Bunyatyan V, Kovalenko SM, Georgiyants V, Ivanauskas L. Development and validation of a HPLC method for quantifica-tion of degradation impurities of salbutamol sulfate with following long-term stability studies in multicomponent cough syrup. Čes. slov. farm. 2020;69(5-6):211-217. doi: 10.36290/csf.2020.029.
Download citation

References

  1. Bezruk I., Kotvitska A., Korzh I., Materiienko A., Gubar S., Budanova L., Ivanauskas L., Vyshnevsky I., Georgiyants V. Combined Approach to the Choice of Chromatographic Methods for Routine Determination of Hederacoside C in Ivy Leaf Extracts, Capsules, and Syrup. Sci. Pharm. 2020; 88(2), 24. Go to original source...
  2. Greunke C., Hage-Hülsmann A., Sorkalla T. A systematic study on the influence of the main ingredients of ivy leaves dry extract on the β2-adrenergic responsiveness of human airway smooth muscle cells. Pulmonary Pharmacology & Therapeutics. 2015; 31, 92-98. Go to original source... Go to PubMed...
  3. Hofmann D., Hecker M. Efficacy of dry extract of ivy leaves in children with bronchial asthma - a review of randomized controlled trials. Phytomedicine 2003; 10, 213-220. Go to original source... Go to PubMed...
  4. Mauryaand C. P., Lokhande M. V. Impurity Profile and Validation of Pharmaceutical (API) Bulk Drug. World Journal of Pharmaceutical Research 2017; 6(11), 878-887. Go to original source...
  5. Churiand S. K., Lokhande M. V. Identification and Impurity Profiling of Process Related Impurities In DTPEE. European Journal of Biomedical and Pharmaceutical Sciences. 2017; 4(9), 617-623.
  6. European Pharmacopoeia 10th ed. 2019. Strasbourg.
  7. Erram S. V., Fanska C. B., Asif M. Determination of albuterol sulfate and its related substances in albuterol sulfate inhalation solution, 0.5% by RP-HPLC. J. Pharm. Biomed. Anal. 2006; 40, 864-874. Go to original source... Go to PubMed...
  8. Malkki L., Tammilehto S. Optimization of the separation of salbutamol and its decomposition products by liquid chromatography with diode-array detection J. Pharm. Biomed. Anal. 1993; 11, 79-84. Go to original source... Go to PubMed...
  9. Beaulieu N., Cyr T. D., Lovering E. G. Liquid chromatographic methods for the determination of albuterol (salbutamol), albuterol sulfate, and related compounds in drug raw materials, tablets, and inhalers. J. Pharm. Biomed. Anal. 1990; 8, 583-589. Go to original source... Go to PubMed...
  10. Ong H., Adam A., Perreault S., Marleau S., Bellemare M., Du Souich P., Beaulieu N. Analysis of albuterol in human plasma based on immunoaffinity chromatographic clean-up combined with high-performance liquid chromatography with fluorimetric detection. J. Chromatogr. 1989; 497, 213-221. Go to original source... Go to PubMed...
  11. Halabi A., Ferrayoli C., Palacio M., Dabbene V., Palacios S. Validation of a chiral HPLC assay for (R)-salbutamol sulfate J. Pharm. Biomed. Anal. 2004; 34, 45-51. Go to original source... Go to PubMed...
  12. Zhang J., Xu Y., Di X., Wu M. Quantitation of salbutamol in human urine by liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2006; 831, 328-332. Go to original source... Go to PubMed...
  13. Weisberger M., Patrick J. E., Powell M. L. Quantitative analysis of albuterol in human plasma by combined gas chromatography chemical ionization mass spectrometry Biomed. Mass Spectrom. 1983; 10, 556-558. Go to original source... Go to PubMed...
  14. Kasawar G. B., Farooqui M. Development, and validation of a stability-indicating RP-HPLC method for the simultaneous determination of related substances of albuterol sulfate and ipratropium bromide in nasal solution. Journal of Pharmaceutical and Biomedical Analysis 2010; 52, 19-29. Go to original source... Go to PubMed...
  15. State Pharmacopoeia of Ukraine 2nd ed. 1st supplement. Kharkiv: State Enterprise "Scientific-and-expert Pharmacopeial Centre" 2015; 1128 pp.
  16. ICH harmonized tripartite guideline Q2 (R1). Validation of analytical procedures: text and methodology Q2 (R1), in Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, 2005.




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.